Anaptysbio, Inc (ANAB): Total Assets
$364.39M
As of 2025-12-31
$329.68M
As of 2026-03-31
-15.8%
3-year compound annual growth
-2.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $364.39M | -24.7% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $483.83M | +7.0% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $452.39M | -25.9% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $610.38M | -5.1% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $643.07M | +54.4% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $416.55M | -4.3% | 2022-03-07, Balance as of period end |
| 2019-12-31 | $435.20M | -14.5% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $509.00M | +54.5% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $329.36M | +429.7% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $62.18M | n/a | 2018-03-05, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $364.39M | -24.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $376.56M | +70.6% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $216.30M | +1.4% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $338.02M | -45.1% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $1.14B | -1.0% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.11B | -1.3% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $726.16M | -11.8% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $670.77M | -2.1% |
Compare ANAB, AKBA, PBYI, KROS side by side · Screen every company in Pharmaceutical Preparations ↗